Changelog

Append-only. Signed. Dated.

Every decision that touches the protocol surface - verifier releases, BioGate parameter changes, council policy shifts, disclosed incidents - appends here. Entries cannot be quietly amended; corrections post as new entries that reference the original.

Build activity · last 26 weeks
631 commits across the public surface
latest week · 44 commits
releaseadr-00092026-04-30
signed · Founderssigned · Interim · clinical pharmacology

v1.3 · Personal layer · Stack, Readiness, Labs, Stack-aware Agent, Practitioner co-sign

First user-facing build of the personal layer. /me/stack tracks active peptides with PDA-V1 vial provenance (verified vs self-reported is a first-class distinction). /me/readiness composites HRV, RHR, sleep efficiency, recovery, and skin-temp deviation from Oura+WHOOP into a daily score. /me/labs ingests PDF lab panels via Kimi K2 file-extract + structured tool-call extraction and graphs assay trends with reference-range bands. The Research Agent gains stack-aware tools (get_user_stack, get_recent_endpoints, get_lab_trends, get_cohort_posterior, submit_proposal) — when authenticated, it stages structured ProposalBundles instead of free-text recommendations. Bundles are NEVER auto-applied: they route to /advisors/inbox where Peptide MD-verified practitioners review the user's frozen brief and return ed25519-signed decisions. /me/stack/[id] now shows cohort-fit posteriors against running OEA-V1 cohorts with an opt-in contribution toggle. /me/stack/import accepts CSV and JSON exports from any peptide tracker via field-alias normalization and attempts PDA-V1 verification against your imported lot bundles. Verifier and oracle surfaces unchanged.

/me/stack ↗/advisors/onboarding ↗/research-agent ↗
releaseadr-00082026-04-28
signed · Founderssigned · Interim · biosecuritysigned · Interim · cryptography

v0.4 launch · Cohort marketplace, dossier PDF, Mol* 3D

First public push of Peptide MD. Includes the cohort registry, the OEA-V1 frozen test vectors, dossier PDF generation under the seven-rule export gate, and Mol* viewer integration for peptides with RCSB structures. Verifier published as @peptide-md/verifier@0.1.0-experimental.1.

/whitepaper ↗@peptide-md/verifier ↗
counciladr-00072026-04-28
signed · Founders

Council policy ratified - interim posture explicit

All six council seats declared open. Until each seat is filled, every protocol-tier promotion and verifier release requires dual sign-off from the founding team plus one remaining seat. The signature record is public on this page.

/advisors ↗
verifieradr-00062026-04-28
signed · Founderssigned · Interim · cryptography

OEA-V1 frozen test vectors published

Three frozen vectors (alpha, beta, gamma) published under CC0. Hashes will not change without a major version bump that ships new vectors alongside. The -9.0 dialect literal edge is exercised by vector beta; the odd-count Merkle duplication rule by vector gamma.

/verifier ↗github · verifier ↗
biogateadr-00052026-04-27
signed · Founderssigned · Interim · biosecurity

BioGate v0.4 public-tier ruleset frozen for v1 launch

Public-tier screen now matches against UniProt toxin profiles, the Australia Group select-agent registry, and a curated cathelicidin-family profile-HMM set. Sequence-window threshold: 8-residue overlap = AMBER, ≥12 = RED. Private-tier review pending biosecurity seat.

adradr-00042026-04-26
signed · Founders

Decision: PDA-V1 ships as a Peptide MD primitive

PDA-V1 design attestations and OEA-V1 reveal attestations form a single cryptographic chain owned end-to-end by Peptide MD. PDA binds peptide design to its inputs; OEA binds the human-use cohort to its endpoint. External design pipelines can submit PDA-V1 bundles via /import-pda; the verifier accepts them under source: "external".

adradr-00032026-04-26
signed · Founders

Decision: closed core, open verification surface

The core orchestration codebase remains private (biosecurity-relevant artifacts, partner-confidential interfaces). The verifier, the test vectors, the white paper, the architecture, the changelog, and the contribution graph are public. Open-trust posture: the code that issues a commitment can stay private, but the code and inputs that verify it cannot.

adradr-00022026-04-25
signed · Founders

Decision: cohort outcomes feed the IPNFT royalty cascade

Cohort treasuries underwrite recruitment and CRO contracts. Royalty cascade splits revealed-OEA outcome revenues 25% / 15% / 35% / 20% / 5% across cohort treasury, participants, originating researchers, stakers, and Peptide MD protocol fee. No native token issuance until jurisdictional review completes; $PMD is a placeholder governance primitive on /token.

/token ↗
adradr-00012026-04-25
signed · Founders

Decision: six-stage Extended Thesis Loop (XTL)

Peptide MD ships a six-stage thesis pipeline: signal intake, novelty scoring, thesis generation, scenario planning, dossier export, and endpoint evaluation. Stage six is the outcome layer - pre-registered cohort runs and OEA reveals attach an outcome-conditioned probability to every candidate that passed the dossier gate.

incidentincident-00012026-04-24
signed · Founders

Pre-launch - no incidents to date

First public surface goes up tomorrow. This entry is the empty marker; the changelog will append every disclosure, every verifier regression, and every BioGate parameter change as they happen.